HAEMATO AG
HAEMATO AG: Q1 2016: Sales growth 50% to EUR 67.94 million, EBIT-growth 100% to EUR 3.47 million, compared to prior year Q1 period
DGAP-News: HAEMATO AG / Key word(s): Quarter Results Corporate News of HAEMATO AG: Q1 2016: Sales growth 50% to EUR 67.94 million, EBIT-growth 100% to EUR 3.47 million, compared to prior year Q1 period In the first quarter 2016 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS Group sales of EUR 69.94 million (prior year period: EUR 45.16 million), an operating result (EBIT) of EUR 3.47 million (prior year period: EUR 1.67 million) and a net profit of EUR 2.59 million (prior year period: EUR 1.23 million). About HAEMATO: HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of the business activities lies on the growth markets of patent free and patent protected medicinal products. Focal points are therapies with cancer, HIV and other chronic diseases. HAEMATO AG is listed in the Entry Standard (Open Market) on the Contact: HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 ir@haemato.de
2016-05-26 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |